Literature DB >> 8840952

Phosphorus accelerates the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failure.

M Denda1, J Finch, E Slatopolsky.   

Abstract

Several studies have suggested that phosphorus (P) restriction, independent of serum levels of ionized calcium and 1,25-(OH)2D3, may prevent parathyroid hyperplasia and secondary hyperparathyroidism in patients and animals with chronic renal failure. A direct role of phosphorus in the pathogenesis of these abnormalities is, however, still controversial. Thus, studies were performed to examine the direct role of phosphorus on the development of these abnormalities. Female Sprague-Dawley rats underwent 5/6 nephrectomy or sham operation. The animals were then divided into two dietary groups (High-P: 0.8% P diet, Low-P: 0.2% P diet). Six to eight rats per group per time-point were killed at the following intervals: 0, 1, 2, and 4 days, and 1, 2, 3, and 4 weeks. Serum intact parathyroid hormone (PTH) levels in uremic rats fed the high-P diet increased 1 day after nephrectomy, and high levels persisted for the duration of the study. Parathyroid gland growth in uremic rats fed the high-P diet was apparent within 2 days of uremia and increased nearly twofold by 2 weeks. These abnormalities, however, did not develop in uremic rats fed the low-P diet. Serum P levels in uremic rats fed the high-P diet were significantly higher than those of uremic rats fed the low-P diet, but there was no significant difference in serum ionized calcium or 1,25-(OH)2D3 levels. These results demonstrate that phosphorus accelerates the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failure, and that phosphorus restriction prevents these abnormalities independent of changes in serum ionized calcium and 1,25-(OH)2D3.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8840952     DOI: 10.1016/s0272-6386(96)90473-4

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  25 in total

Review 1.  Renal osteodystrophy.

Authors:  E A González; K J Martin
Journal:  Rev Endocr Metab Disord       Date:  2001-04       Impact factor: 6.514

2.  Demographic, dietary, and serum factors and parathyroid hormone in the National Health and Nutrition Examination Survey.

Authors:  J M Paik; W R Farwell; E N Taylor
Journal:  Osteoporos Int       Date:  2011-09-20       Impact factor: 4.507

Review 3.  FGF23 and PTH--double agents at the heart of CKD.

Authors:  Justin Silver; Mariano Rodriguez; Eduardo Slatopolsky
Journal:  Nephrol Dial Transplant       Date:  2012-03-23       Impact factor: 5.992

4.  The calcimimetic NPS R-568 decreases plasma PTH in rats with mild and severe renal or dietary secondary hyperparathyroidism.

Authors:  J Fox; S H Lowe; R L Conklin; E F Nemeth
Journal:  Endocrine       Date:  1999-04       Impact factor: 3.633

Review 5.  Regulation of parathyroid function in chronic renal failure.

Authors:  Mariano Rodriguez; Sagrario Cañadillas; Ignacio Lopez; Escolástico Aguilera-Tejero; Yolanda Almaden
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

6.  Phosphorylation of Ribosomal Protein S6 Mediates Mammalian Target of Rapamycin Complex 1-Induced Parathyroid Cell Proliferation in Secondary Hyperparathyroidism.

Authors:  Oded Volovelsky; Gili Cohen; Ariel Kenig; Gilad Wasserman; Avigail Dreazen; Oded Meyuhas; Justin Silver; Tally Naveh-Many
Journal:  J Am Soc Nephrol       Date:  2015-08-17       Impact factor: 10.121

7.  Activator protein 2alpha mediates parathyroid TGF-alpha self-induction in secondary hyperparathyroidism.

Authors:  Maria Vittoria Arcidiacono; Mario Cozzolino; Noah Spiegel; Masanori Tokumoto; Jing Yang; Yan Lu; Tetsuhiko Sato; Carlo Lomonte; Carlo Basile; Eduardo Slatopolsky; Adriana S Dusso
Journal:  J Am Soc Nephrol       Date:  2008-06-25       Impact factor: 10.121

8.  EGFR activation increases parathyroid hyperplasia and calcitriol resistance in kidney disease.

Authors:  Maria Vittoria Arcidiacono; Tetsuhiko Sato; Daniel Alvarez-Hernandez; Jing Yang; Masanori Tokumoto; Ignacio Gonzalez-Suarez; Yan Lu; Yoshihiro Tominaga; Jorge Cannata-Andia; Eduardo Slatopolsky; Adriana S Dusso
Journal:  J Am Soc Nephrol       Date:  2008-01-23       Impact factor: 10.121

Review 9.  Hyperphosphatemia of chronic kidney disease.

Authors:  Keith A Hruska; Suresh Mathew; Richard Lund; Ping Qiu; Raymond Pratt
Journal:  Kidney Int       Date:  2008-04-30       Impact factor: 10.612

Review 10.  Mineral metabolism and bone abnormalities in children with chronic renal failure.

Authors:  Cheryl P Sanchez
Journal:  Rev Endocr Metab Disord       Date:  2008-01-04       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.